Innovations in cell therapy manufacturing and immuno-oncology were highlighted by Cellares’ unveiling of its fully automated Cell Q quality control platform, designed to scale commercial cell therapy production by automating labor-intensive release assays. Additional developments include Shape Therapeutics’ $1.2 billion agreement with Vectory Therapeutics for use of a brain-penetrating AAV capsid enabling in vivo vectorized antibody delivery for neurodegenerative diseases. Clinical-stage biotech advancements continue to push the frontier in autoimmune and oncology therapeutics.